Saturday 7 November 2026 Export DCOY’s income statement to Excel — free account

Decoy Therapeutics Inc

DCOY Healthcare Biotechnology

Revenue: −84.6%
EPS: +94.5%
Free cash flow: −212.5%

Quarter to June 2026, against a year earlier

1.13 0.01 +0.89%

Follow DCOY

Alert me

Market cap: $2.7M
P/E: 0.0×
Fwd P/E: −2.5×
Dividend yield: —
F-score: 4/9
Altman Z: 4.56
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 0.00

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 2.67

Revenue ttm 2.07

Net income ttm (14.45)

Free cash flow ttm (8.94)

Net debt Q (8.29)

Valuation

P/E 0.00

Forward P/E (2.45)

Price / sales 0.29

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.14

Financial health

Current ratio Q 1.83

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q −84.61%

Operating income growth Q −148.90%

EPS, this year +77.55%

EPS, next year A −48.48%

Revenue, next year A −100.00%

EPS, past 5 yrs —

EPS, next 5 yrs A +80.05%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 3.85%

10-year low 10-year high

P/B against its own 10 years 1.73%

10-year low 10-year high

EV/FCF against its own 10 years 65.68%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6	2	11	8
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	7	3	11	9

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	0	—
	1	2	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	12.73%	(1.94%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(24.05%)	(23.28%)	(17.23%)

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(4.18)	(4.46)	—	—	—
’25	(184.93)	(81.21)	(21.77)	(27.48)	(129.10)
’24	(588.86)	(427.02)	(136.50)	(182.70)	(1.04k)
’23	(3.22k)	(2.06k)	(937.03)	(302.09)	(5.53k)
’22	(4.75k)	(3.17k)	(9.23k)	(4.06k)	(21.42k)
’21	(2.18k)	(2.47k)	(3.00k)	(3.26k)	(11.11k)
’20	(7.87k)	(4.60k)	(3.44k)	(3.73k)	(17.91k)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	0	—	—	—
’21	1	1	—	0	2
’20	1	1	1	1	5
’19	1	1	1	1	3
’18	0	0	0	1	2
’17	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(1)	(1)	(2)	(1)	(5)
’24	(1)	(1)	(1)	(1)	(5)
’23	(3)	(4)	(4)	(2)	(13)
’22	(4)	(4)	(6)	(5)	(18)
’21	(3)	(3)	(2)	(3)	(10)
’20	(4)	(2)	(3)	(1)	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(1)	(1)	(2)	(2)	(5)
’24	(1)	(1)	(1)	(1)	(5)
’23	(3)	(4)	(4)	(2)	(13)
’22	(5)	(4)	(6)	(5)	(19)
’21	(3)	(3)	(2)	(3)	(10)
’20	(4)	(2)	(3)	(1)	(10)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	1	1	2	3	5	2	—	—	—	—	2		+12.7%	—	—	—	—
	Gross margin, %	34.42	60.26	100.00	100.00	100.00	100.00	0.00	—	—	—	10.57		(34.4) pt	Powerpack Decoy Therapeutics Inc’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(39)	(34)	(2)	(7)	(7)	(13)	(32)	(13)	(6)	(13)	(14)		(12.0%)
	EBT margin, %	(3,907.50)	(2,701.74)	(85.56)	(200.18)	(140.49)	(693.85)	0.00	0.00	0.00	0.00	(698.79)		+3,907.5 pt
	Net income	(39)	(34)	(2)	(7)	(7)	(13)	(32)	(13)	(6)	(13)	(14)		(12.0%)
Per share, $
Per share, $	Revenue	56,025.50	66,449.43	45,636.11	38,161.89	12,093.40	1,601.50	0.00	0.00	0.00	0.00	3.89		n/m
	Earnings	(2,189,467.96)	(1,795,434.88)	(41,940.30)	(76,394.78)	(17,906.17)	(11,111.92)	(21,424.00)	(5,532.49)	(1,043.06)	(129.10)	(57.89)		(66.1%)
	Cash flow	(1,776,723.95)	(1,445,370.18)	97,689.43	(127,534.14)	(23,828.16)	(8,877.07)	(11,926.19)	(5,666.31)	(846.55)	(49.78)	(15.65)		(68.8%)
	Capex	(30,715.08)	(5,641.29)	112.25	0.00	(6.01)	0.00	(1,016.71)	0.00	0.00	(5.95)	(1.16)		(61.3%)
	Free cash flow	(1,807,439.02)	(1,451,011.47)	97,801.68	(127,534.14)	(23,834.17)	(8,877.07)	(12,942.89)	(5,666.31)	(846.55)	(55.73)	(16.81)		(68.5%)
	Book value	3,288,104.21	1,517,513.03	(29,726.38)	116,529.74	51,206.73	33,700.01	7,038.74	2,332.19	282.79	60.73	8.12		(70.2%)
	Shares, m	0	0	0	0	0	0	0	0	0	0	0		+159.7%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	0.00		0.0
	P/S	0.00	49.28	8.17	4.45	3.63	6.77	—	—	—	—	0.29		12.0
	P/B	1.50	2.16	0.00	1.46	0.86	0.58	—	—	—	—	0.14		1.1
	EV/Sales	0.00	23.13	5.03	3.59	1.59	(1.89)	—	—	—	—	(3.49)		5.2
	EV/FCF	(0.86)	(1.06)	2.35	(1.07)	(0.81)	0.61	—	—	—	—	0.69		(0.1)
Cash, $m
Cash, $m	Operating cash flow	(32)	(28)	4	(12)	(10)	(10)	(18)	(13)	(5)	(5)	(8)		(19.0%)
	Capex	(1)	0	0	—	0	—	(1)	—	—	(1)	(1)		+0.5%
	Free cash flow	(33)	(28)	4	(12)	(10)	(10)	(19)	(13)	(5)	(5)	(9)		(18.1%)
Balance, $m
Balance, $m	Working capital	59	29	(2)	1	14	28	10	5	1	6	4		(22.6%)
	Net debt	(61)	(33)	(6)	(4)	(11)	(29)	(12)	(6)	(2)	(11)	(8)		(17.6%)
	Shareholders’ equity	59	29	(1)	11	22	39	10	5	2	6	4		(22.6%)
Returns, %
Returns, %	ROA	(49.90)	(70.12)	(8.62)	(67.64)	(39.91)	(38.83)	(113.93)	(118.12)	(116.05)	(177.82)	(278.04)		(127.9) pt
	ROIC	0.00	0.00	0.00	(75.50)	(42.25)	(84.22)	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	(52.13)	(77.88)	(12.89)	(149.01)	(47.33)	(41.94)	(128.73)	(160.07)	(164.02)	(338.31)	(827.77)		(286.2) pt
People
People	Employees	31	22	4	7	10	16	12	2	2	11	—		(10.9%)
	Revenue/emp, $m	0.03	0.06	0.49	0.50	0.52	0.12	0.00	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2021 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KALA KALA BIO, Inc.	$3.0M	— (loss-making)	— (loss-making)	−86.31% (below 0%: shrinking)	n/m	+80.19% (above 0%: growing)	0.00%	0.00%	Compare
BCAB BioAtla, Inc.	$2.9M	— (loss-making)	— (loss-making)	+4,233.33% (above 0%: growing)	n/m	+97.03% (above 0%: growing)	100.00%	3.49%	Compare
JUNS Jupiter Neurosciences, Inc.	$2.8M	— (loss-making)	—	—	n/m	−177.06% (below 0%: shrinking)	87.19%	(11,334.30%)	Compare
AFMDQ Affimed N.V.	$2.8M	— (loss-making)	— (loss-making)	−92.02% (below 0%: shrinking)	n/m	+46.95% (above 0%: growing)	100.00%	(9,216.90%)	Compare
DCOY Decoy Therapeutics Inc	$2.7M	— (loss-making)	— (loss-making)	−84.61% (below 0%: shrinking)	n/m	−212.47% (below 0%: shrinking)	100.00%	(1,055.98%)
NRSN NeuroSense Therapeutics Ltd.	$2.6M	— (loss-making)	—	—	n/m	−23,458.82% (below 0%: shrinking)	—	0.00%	Compare
EOCN Eocene Ltd.	$2.6M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−67.74% (below 0%: shrinking)	0.00%	0.00%	Compare
BIORQ Biora Therapeutics, Inc.	$2.5M	— (loss-making)	— (loss-making)	+1,500.00% (above 0%: growing)	n/m	+20.72% (above 0%: growing)	100.00%	(50,709.38%)	Compare
CLDI Calidi Biotherapeutics, Inc.	$2.5M	— (loss-making)	—	—	n/m	+11.16% (above 0%: growing)	—	0.00%	Compare
Median of peers	$2.7M	—	—	−86.31%	—	+15.94%	93.60%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 4 August 2026

Ownership

Directors and executive officers, together 1.50%

CVI Investments, Inc. 9.99%

Armistice Capital Master Fund Ltd. 9.86%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Decoy Therapeutics Inc (DCOY) Latest News

29 Sep

Impact 4 · 7:30 AM · PR Newswire

Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program

22 Sep

Impact 4 · 2:03 PM · PR Newswire

/C O R R E C T I O N -- Decoy Therapeutics, Inc/

Impact 4 · 12:50 PM · PR Newswire

Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules

Impact 4 · 7:30 AM · PR Newswire

Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding

3 Aug

Impact 4 · 9:00 AM

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

27 Jul

Impact 4 · 9:00 AM

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

29 Jun

Impact 4 · 11:41 AM · Stocktwits

DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally?

26 Jun

Impact 4 · 8:11 PM

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

1 Jun

Impact 4 · 7:00 AM · PR Newswire

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

9 Apr

Impact 4 · 8:36 AM · PR Newswire

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

2 Apr

Impact 4 · 9:00 AM · PR Newswire

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

11 Mar

Impact 4 · 8:30 AM · PR Newswire

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

5 Mar

Impact 3 · 8:30 AM · PR Newswire

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

11 Feb

Impact 3 · 9:00 AM

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

4 Feb

Impact 4 · 9:02 AM

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

13 Jan

Impact 4 · 8:15 AM · PR Newswire

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

7 Jan

Impact 4 · 8:45 AM · GlobeNewswire

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

18 Dec

Impact 4 · 7:50 AM · GlobeNewswire

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

17 Dec

Impact 4 · 8:47 AM

NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio

1 Dec

Impact 3 · 8:00 AM · GlobeNewswire

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

19 Nov

Impact 4 · 9:52 AM · GlobeNewswire

Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies

14 Nov

Impact 3 · 5:35 PM · Associated Press FinanceMT NewswiresAssociated Press FinanceAssociated Press Finance

Salarius: Q3 Earnings Snapshot

13 Nov

Impact 4 · 8:45 AM · GlobeNewswire

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

12 Nov

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

11 Nov

Impact 3 · 9:15 AM · PR Newswire

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

13 Oct

Impact 3 · 8:45 AM · GlobeNewswireMT NewswiresMT NewswiresPharmaceutical TechnologyMT NewswiresInsider Monkey

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

9 Sep

Impact 3 · 8:00 AM · GlobeNewswire

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

14 Aug

Impact 3 · 8:30 AM · GlobeNewswire

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

12 Aug

Impact 3 · 5:35 PM · Associated Press Finance

Salarius: Q2 Earnings Snapshot

29 Jul

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Decoy Therapeutics Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 4 August 2026

Ownership

Decoy Therapeutics Inc (DCOY) Latest News

29 Sep

22 Sep

3 Aug

27 Jul

29 Jun

26 Jun

1 Jun

9 Apr

2 Apr

11 Mar

5 Mar

11 Feb

4 Feb

13 Jan

7 Jan

18 Dec

17 Dec

1 Dec

19 Nov

14 Nov

13 Nov

12 Nov

11 Nov

13 Oct

9 Sep

14 Aug

12 Aug

29 Jul

Stockrow Weekly